Roche on Friday reported two-year results from the Phase IIIb/IV SALWEEN study of Vabysmo (faricimab), demonstrating sustained improvements in vision and retinal health for patients with polypoidal choroidal vasculopathy (PCV), a severe subtype of neovascular age-related macular degeneration.
The data, presented at a medical meeting, highlight the long-term efficacy and durability of Vabysmo in treating PCV, a condition prevalent in Asia and historically difficult to manage. Roche’s Chief Medical Officer and Head of Global Product Development, Levi Garraway, said the findings underscore the drug’s sustained benefit in a challenging patient population.
Vabysmo, the first bispecific antibody approved for ophthalmic use, is currently cleared in over 100 countries for neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. It also holds approvals in more than 60 countries, including the U.S., EU and Japan, for macular edema following retinal vein occlusion.
Roche’s shares were down 0.66% at 361.60 Swiss francs on the SIX Swiss Exchange at the time of the announcement.
